News

October 2011, New Century licenses magnetic properties of its Ferrigen platform to Integrated Magnetic Systems in Dundee, Scotland. Read More »

2010 New Century published overview of its CADEX albumin structural survey as an invited chapter in Burger’s Drug Design and Development: D.C. Carter, “Crystallographic Survey of Albumin Drug Interaction and Applications in Cancer Chemotherapy,” Burger’s Drug Design and Development, 7th Edition, John Wiley & Sons; 437-468 (2010).

December 2010, F-star licenses therapeutic applications with Boehringer Ingelheim. Read More »

May 2009, New Century licenses its recombinant product portfolio to Albumin Therapeutics. Read More »

New Investment Opportunity: New Century Pharmaceuticals announces its pending August 2008 stock offering to fund the Company's first Phase I clinical trial. Read More »

June 2008, New Century Pharmaceuticals, Inc., one of the Hudson Alpha Associate Companies, establishes initial office presence at the Hudson Alpha Institutes new state-of-the-art facilities. Read More »

Bob Crutchfield, CEO of Third Trimester and former VP of US Oncology, is engaged by the Company as a senior advisor in support of business operations and development. Read More »

May 23, 2008 NCP successfully retires bridge financing through sale of its royalty interest in modular antibody platform licensed to f-star, an Austrian based biopharmaceutical company. Read More »

In the first quarter of 2006, New Century Pharmaceuticals, Inc. jointly engaged Harpeth Capital, LLC and BioPharm Development Group, LLC. Harpeth Capital is a middle-market investment banking firm based in Nashville, Tennessee focusing primarily in healthcare. BioPharm is a biotech and pharmaceutical consulting firm also based in Nashville, Tennessee.

NCP's ferritin technology platform featured on the cover of the summer issue of the journal Industrial Biotechnology. The work provided a dramatic demonstration of the platform on an HIV vaccine application.
See more »

The Company's first Ferrigen patent entitled, "Ferritin Fusion Proteins for use in Vaccines and other Applications," issues on August 29th, 2006, U.S. Patent No. 7,097,841.